ipriflavone has been researched along with Low Bone Density in 3 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The safety profiles were associated with adverse events and the number of subject withdrawals due to adverse reactions." | 2.66 | The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis. ( Chen, J; Hu, Q; Huang, S; Long, C; Ning, N; O Klineberg, E; Ran, L; Wu, D; Xu, J; You, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Q | 1 |
| Long, C | 1 |
| Wu, D | 1 |
| You, X | 1 |
| Ran, L | 1 |
| Xu, J | 1 |
| O Klineberg, E | 1 |
| Huang, S | 1 |
| Chen, J | 1 |
| Ning, N | 1 |
| Gambacciani, M | 1 |
| Spinetti, A | 1 |
| Piaggesi, L | 1 |
| Cappagli, B | 1 |
| Taponeco, F | 1 |
| Manetti, P | 1 |
| Weiss, C | 1 |
| Teti, GC | 1 |
| La Commare, P | 1 |
| Facchini, V | 1 |
| Ohta, H | 1 |
| Komukai, S | 1 |
| Makita, K | 1 |
| Masuzawa, T | 1 |
| Nozawa, S | 1 |
1 review available for ipriflavone and Low Bone Density
| Article | Year |
|---|---|
The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Female; H | 2020 |
2 trials available for ipriflavone and Low Bone Density
| Article | Year |
|---|---|
Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
Topics: Adult; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Dou | 1994 |
Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
Topics: Adult; Biomarkers; Bone Density; Bone Diseases, Metabolic; Female; Humans; Isoflavones; Lumbar Verte | 1999 |